These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 11499697)
1. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens. Burdin N; Moingeon P Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697 [TBL] [Abstract][Full Text] [Related]
2. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
3. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568 [TBL] [Abstract][Full Text] [Related]
4. Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines. Dobrovolskienė N; Pašukonienė V; Darinskas A; Kraśko JA; Žilionytė K; Mlynska A; Gudlevičienė Ž; Mišeikytė-Kaubrienė E; Schijns V; Lubitz W; Kudela P; Strioga M Vaccine; 2018 Jul; 36(29):4171-4180. PubMed ID: 29895501 [TBL] [Abstract][Full Text] [Related]
5. Advances in dendritic cell-based vaccine of cancer. Zhang X; Gordon JR; Xiang J Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664 [TBL] [Abstract][Full Text] [Related]
7. Loading DCs with Ag. Vari F; Hart DN Cytotherapy; 2004; 6(2):111-21. PubMed ID: 15203987 [TBL] [Abstract][Full Text] [Related]
8. Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. Ni M; Hoffmann JM; Schmitt M; Schmitt A Expert Opin Biol Ther; 2016 Sep; 16(9):1113-23. PubMed ID: 27238400 [TBL] [Abstract][Full Text] [Related]
10. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Timmerman JM; Levy R J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787 [TBL] [Abstract][Full Text] [Related]
11. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333 [TBL] [Abstract][Full Text] [Related]
14. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. Willemen Y; Van den Bergh JM; Bonte SM; Anguille S; Heirman C; Stein BM; Goossens H; Kerre T; Thielemans K; Peeters M; Van Tendeloo VF; Smits EL; Berneman ZN Oncotarget; 2016 Nov; 7(45):73960-73970. PubMed ID: 27659531 [TBL] [Abstract][Full Text] [Related]
15. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Tacken PJ; de Vries IJ; Torensma R; Figdor CG Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902 [TBL] [Abstract][Full Text] [Related]
16. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
17. Genetically modified tumour vaccines--where we are today. Nawrocki S; Mackiewicz A Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588 [TBL] [Abstract][Full Text] [Related]
18. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Bodey B; Bodey B; Siegel SE; Kaiser HE Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341 [TBL] [Abstract][Full Text] [Related]